GREAT NECK, N.Y., Jan. 14 /PRNewswire/ -- Scarguard Labs, LLC, a closely held company specializing in the treatment of scars and other dermatological problems through the use of multi-technology drugs enhanced by a proprietary contact delivery system, announced it has appointed Richard E. Pino as Chief Financial Officer. He will be responsible for the Company's finance, accounting, and treasury functions and will report to Chief Executive Officer, Joel Studin, MD.
Prior to his appointment, Mr. Pino served as Chief Financial Officer / Chief Operating Officer for EcoSys Management LLC, a leader in enterprise project and operations financial management solutions. While there, Mr. Pino was responsible for overall operations: Finance, HR, Legal and Facilities. Previously, Mr. Pino was the Chief Financial Officer for The Relegence Corporation, which became a wholly-owned subsidiary of AOL, a TimeWarner Company during Pino's tenure.
From 2001 through 2005, Pino was the CFO for Frontline Communications International, Inc. where he was responsible for overall operations as well as overseeing outside accounting, tax and legal firms. Prior to 2001, Mr. Pino held various financial positions in of the following industries: Telecom, investment banking and media. He currently serves in a financial capacity on the boards of several non-profit organizations, including The Brooklyn Philharmonic and the Museum of Biblical Art.
Mr. Pino received his BA from
Speaking of Mr. Pino's appointment, Dr. Studin said, "We couldn't be happier that Richard agreed to join our Company. His experience covers all aspects of the finance, treasury and accounting roles, and includes strategic planning, mergers and acquisitions, all roles that he will fulfill while at Scarguard. He will be a key part of Scarguard's growth as a company."
About Scarguard Labs, LLC.
Scarguard Labs, LLC is a closely held pharmaceutical company specializing in dermatological medications employing an internationally patented delivery system designed to enhance drug effectiveness utilizing a multi-technology approach. Our flagship product, Scarguard, is the most frequently dispensed product for scars in plastic surgery offices since 2001. In addition, it can be found in most pharmacies, drug distributors and major grocery chains throughout the United States. We have multiple topical prescription and non-prescription drugs in the marketplace, or in varying stages of development. For more information, please visit our website at www.scarguard.com
Company Contact: Richard E. Pino Chief Financial Officer /Investor Relations Scarguard Labs, LLC 516-482-8050 Richard@scarguard.com Investor Relations: John McNamara Cameron Associates (212) 245-8800 Ext. 205 email@example.com
|SOURCE Scarguard Labs, LLC|
Copyright©2009 PR Newswire.
All rights reserved